以CAR-T疗法为代表的细胞免疫疗法的出现,为肿瘤患者带来了新的希望,得益于CAR-T疗法,让很多难治性、复发性血液系统恶性肿瘤获得了持续缓解,甚至存在“临床治愈”的希望。 截至2023年,ClinicalTrials.gov数据显示,全球免疫细胞治疗的临床研究...
Chen, X. et al. (2023) 'Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.,' Journal of Clinical Oncology, 41(16_su...
[5]https://www.clinicaltrialsarena.com/news/cellectis-car-t-cell-therapies-2023/?cf-view [6]https://lymphomahub.com/medical-information/dual-targeted-car-t-cell-therapy-key-updates-from-tct-2023 [7]https://www.glpg.com/press-releases/galapagos-presents-new-encouraging-data-at-ash-2023-fro...
CAR-T致死今年已是第 6 例 8月 18 日,据外媒报道,生物制药公司 Poseida(Nasdaq:PSTX)正在进行的一项 CAR-T 临床试验因发生患者死亡而被 FDA 叫停,Poseida 股价因此遭遇暴跌,近三分之一市值“蒸发”。仅在一个月前,同样的事情还发生在知名细胞治疗公司 Cellectis 身上,其 CAR-T 临床试验同样因患者死亡而被 ...
[4]https://healthtree.org/myeloma/community/articles/gprc5d-targeted-car-t-therapies-ash-2023 [5]https://www.clinicaltrialsarena.com/news/cellectis-car-t-cell-therapies-2023/?cf-view [6]https://lymphomahub.com/medical-information/dual-targeted-car-t-cell-therapy-key-updates-from-tct-2023 ...
Taken together, these interim results indicate that CT041 has the potential to become an important treatment modality for patients with advanced GC, suggesting that CAR T cell therapy could benefit not only patients with hematologic malignancies but also those with solid tumors. CT041 showed a trend...
截至2022年4月,已有近1000项CAR-T治疗实体瘤的临床试验正在进行中(ClinicalTrials.gov),这表明CAR-T疗法在实体瘤领域的适用范围正在逐步扩大。本研究源于一项临床试验,旨在探讨CT041在患者体内的动态变化。研究发现,体内CAR-T细胞的扩增在治疗后7天达到峰值,且腹水中的CAR-T细胞扩增程度明显高于外周血。治疗前外周血中...
2.Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase 1 Trials. Clinical Cancer Research.2020. DOI: 10.1158/1078-0432.CCR-19-3259
Chimeric antigen receptor redirected T cells (CAR-T cells) have achieved inspiring outcomes in patients with B cell malignancies, and are now being investigated in other hematologic malignancies and solid tumors. CAR-T cells are generated by the T cells from patients’ or donors’ blood. After ...
据clinicaltrials.gov显示LM-302已进入临床Ⅲ试验，适应症为CLDN18.2阳性局部晚期或转移性胃/胃食管交界处腺癌。CAR-T CAR-T一直受到靶点选择、实体瘤高异质性、免疫微环境抑制等难题的困扰，Claudin18.2强大的特异性使其成为实体瘤CAR-T领域的热门。国内已有多家公司布局Claudin18.2 CAR-T治疗，如科济药业、隆耀...